We consider some of the remaining key questions for Medicare’s real-world data collection strategy for emerging Alzheimer’s therapies, focusing on how the plan might impact both evidence generation and patient access.
We consider some of the remaining key questions for Medicare’s real-world data collection strategy for emerging Alzheimer’s therapies, focusing on how the plan might impact both evidence generation and patient access.